Evaluation of Sympathetic Skin Response and Its Relationship With Clinical Response to Complex Decongestive Therapy in Patients With Postmastectomy Lymphedema (BCRL-SSR)
This prospective observational single-center study aimed to evaluate sympathetic skin response (SSR) in patients with postmastectomy upper extremity lymphedema and to investigate the relationship between SSR parameters and clinical response to complex decongestive therapy (CDT).
Thirty female patients with breast cancer-related lymphedema and thirty healthy female controls were included in the study. All participants underwent autonomic nervous system assessment using SSR and R-R interval variability measurements and completed the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire.
Patients in the lymphedema group received a standardized 3-week CDT program consisting of 15 treatment sessions. Clinical response to treatment was evaluated by calculating changes in lymphedema volume before and after treatment. Quality of life, upper extremity function, pain severity, and neuropathic pain symptoms were assessed using LYMQOL-Arm, QuickDASH, Numeric Rating Scale (NRS), and Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
Visão geral do estudo
Status
Descrição detalhada
Breast cancer-related lymphedema is a chronic condition that develops following breast cancer treatment and is traditionally considered to result from impaired lymphatic drainage and fluid accumulation. Recent evidence suggests that autonomic nervous system dysfunction may also contribute to the pathophysiology of lymphedema.
The aim of this prospective observational study was to evaluate sympathetic skin response (SSR), autonomic nervous system functions, and their relationship with clinical response to complex decongestive therapy (CDT) in patients with postmastectomy upper extremity lymphedema.
Thirty female patients aged 18-65 years with unilateral upper extremity lymphedema after breast cancer treatment and thirty healthy female controls were included. All participants underwent electrophysiological autonomic nervous system evaluation using SSR and R-R interval variability measurements. In addition, autonomic symptoms were assessed using the Composite Autonomic Symptom Score-31 (COMPASS-31).
Patients in the lymphedema group received a standardized CDT program for 3 weeks, 5 days per week, totaling 15 sessions. Clinical response to treatment was evaluated using changes in lymphedema volume measurements obtained before and after treatment.
Secondary clinical assessments included quality of life evaluation with LYMQOL-Arm, upper extremity functional assessment with QuickDASH, pain severity assessment using the Numeric Rating Scale (NRS), and neuropathic pain evaluation using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
The study aimed to determine whether autonomic dysfunction is present in breast cancer-related lymphedema and whether baseline SSR parameters are associated with clinical response to CDT.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Ankara
-
Ankara, Ankara, Turquia (Türkiye), 06800
- Gaziler Physical Medicine and Rehabilitation Training and Research Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Healthy Control Inclusion Criteria:
- Female volunteers aged between 18 and 65 years
- No history of breast cancer or lymphedema
- No neurological, metabolic, or systemic disease affecting autonomic nervous system function
Healthy Control Exclusion Criteria:
- History of breast cancer or lymphedema
- Polyneuropathy
- Diabetes mellitus
- Hypothyroidism
- Neurological disease
- Systemic diseases affecting autonomic nervous system function
Patient group;
Inclusion Criteria:
Inclusion Criteria:
- Female patients aged between 18 and 65 years
- Postmastectomy upper extremity lymphedema after breast cancer surgery
- Completion of breast cancer treatment protocols
- International Society of Lymphology (ISL) stage I-II lymphedema
Exclusion Criteria:
- Metastatic breast cancer
- Bilateral breast cancer history
- Bilateral upper extremity lymphedema
- Ongoing chemotherapy or radiotherapy
- Infection or allergic skin lesions on the upper extremities
- Medical conditions causing edema, including decompensated heart, lung, or renal failure
- Peripheral nervous system disease or polyneuropathy
- Chronic endocrine, metabolic, neurological, or systemic diseases affecting autonomic nervous system function, including diabetes mellitus, hypo/hyperthyroidism, uremia, heart failure, cardiac arrhythmia, and uncontrolled hypertension
- Presence of a cardiac pacemaker
- Inability to tolerate electrical stimulation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Lymphedema volume difference and sympathetic skin response (SSR) parameters
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Upper extremity lymphedema volume difference and sympathetic skin response (SSR) parameters were evaluated before and after complex decongestive therapy.
Limb volume was calculated using circumferential measurements obtained at 4-cm intervals with the truncated cone formula.
SSR recordings were obtained using surface electrodes and median nerve stimulation.
Peak-to-peak amplitude and latency values were analyzed.
|
Baseline and after 3 weeks of complex decongestive therapy
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
R-R interval variability (RRIV)
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Cardiac autonomic function was evaluated using R-R interval variability measurements during resting and deep breathing conditions.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
COMPASS-31 score
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Autonomic symptoms were evaluated using the Composite Autonomic Symptom Score-31 questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
LYMQOL-Arm score
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Quality of life related to upper extremity lymphedema was evaluated using the LYMQOL-Arm questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
QuickDASH score
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Upper extremity functional status was assessed using the QuickDASH questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
Numeric Rating Scale (NRS)
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Pain severity was evaluated using the Numeric Rating Scale.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
Prazo: Baseline and after 3 weeks of complex decongestive therapy
|
Neuropathic pain symptoms were evaluated using the LANSS questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Complicações pós-operatórias
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Doenças de pele
- Doenças da mama
- Doenças Linfáticas
- Doenças do Sistema Nervoso Autônomo
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Doenças hemic e linfáticas
- Câncer de Mama Linfedema
- Neoplasias da Mama
- Linfedema
- Disautonomias primárias
Outros números de identificação do estudo
- BCRL-SSR-2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .